YUNNAN BOTANEE BIO-TECHNOLOGY GROUP CO.LTD Financials Yunnan Botanee Bio-Technology Group Co.LTD
Equities
300957
CNE100004G74
Personal Products
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.4 CNY | -0.32% |
|
-3.09% | -21.67% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 81,450 | 63,218 | 28,877 | 22,460 | - | - |
| Enterprise Value (EV) 1 | 79,464 | 60,766 | 26,936 | 19,875 | 19,336 | 18,976 |
| P/E ratio | 90.7 x | 60.2 x | 38.1 x | 20.2 x | 15.4 x | 15.1 x |
| Yield | 0.31% | 0.54% | 0.88% | 1.45% | 1.77% | 1.98% |
| Capitalization / Revenue | 20.2 x | 12.6 x | 5.23 x | 3.21 x | 2.64 x | 2.45 x |
| EV / Revenue | 19.8 x | 12.1 x | 4.88 x | 2.84 x | 2.27 x | 2.07 x |
| EV / EBITDA | 75.7 x | 47.7 x | 27.3 x | 14.4 x | 11.4 x | 10.7 x |
| EV / FCF | 90.1 x | 146 x | 79.4 x | 16.8 x | 14.2 x | 12.9 x |
| FCF Yield | 1.11% | 0.68% | 1.26% | 5.95% | 7.04% | 7.77% |
| Price to Book | 17.1 x | 11.4 x | 4.93 x | 3.36 x | 2.81 x | 2.53 x |
| Nbr of stocks (in thousands) | 423,600 | 423,600 | 423,600 | 420,605 | - | - |
| Reference price 2 | 192.3 | 149.2 | 68.17 | 53.40 | 53.40 | 53.40 |
| Announcement Date | 3/22/22 | 3/29/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4,022 | 5,014 | 5,522 | 6,996 | 8,513 | 9,168 |
| EBITDA 1 | 1,050 | 1,273 | 985.9 | 1,385 | 1,689 | 1,779 |
| EBIT 1 | 1,016 | 1,212 | 878 | 1,201 | 1,613 | 1,637 |
| Operating Margin | 25.25% | 24.18% | 15.9% | 17.16% | 18.94% | 17.85% |
| Earnings before Tax (EBT) 1 | 1,018 | 1,214 | 868.8 | 1,277 | 1,665 | 1,710 |
| Net income 1 | 862.9 | 1,051 | 756.8 | 1,138 | 1,488 | 1,506 |
| Net margin | 21.45% | 20.97% | 13.7% | 16.27% | 17.48% | 16.43% |
| EPS 2 | 2.120 | 2.480 | 1.790 | 2.640 | 3.465 | 3.547 |
| Free Cash Flow 1 | 882.3 | 416 | 339.1 | 1,182 | 1,360 | 1,474 |
| FCF margin | 21.93% | 8.3% | 6.14% | 16.9% | 15.98% | 16.07% |
| FCF Conversion (EBITDA) | 84.01% | 32.68% | 34.39% | 85.36% | 80.54% | 82.83% |
| FCF Conversion (Net income) | 102.24% | 39.58% | 44.8% | 103.86% | 91.45% | 97.82% |
| Dividend per Share 2 | 0.6000 | 0.8000 | 0.6000 | 0.7726 | 0.9475 | 1.057 |
| Announcement Date | 3/22/22 | 3/29/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,910 | 808.5 | 1,241 | 2,050 | 845.8 | 2,118 | 863.3 | 1,504 | 2,368 | 1,064 | 2,091 | 3,154 | - | 1,779 | 1,248 | 2,962 | - | - |
| EBITDA 1 | - | - | 213.3 | - | - | - | - | - | - | - | - | - | - | 384 | - | - | - | - |
| EBIT 1 | 594.7 | 175.6 | 291.3 | 466.9 | 132.6 | 612.6 | 180.2 | 317.2 | - | 139 | 241.6 | 380.5 | - | 293.1 | 131.1 | 466.2 | - | - |
| Operating Margin | 31.14% | 21.72% | 23.47% | 22.78% | 15.68% | 28.92% | 20.87% | 21.09% | - | 13.07% | 11.55% | 12.06% | - | 16.47% | 10.51% | 15.74% | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | - | 133 | 614 | - | 338.7 | 512.7 | 137.8 | 240 | - | - | 301.8 | 125.9 | 538.8 | - | - |
| Net income 1 | - | - | 249.1 | 395 | 122.3 | 533.9 | - | 291.7 | 450 | 129.2 | 177.6 | 306.8 | - | 251.1 | 99.63 | 461.8 | - | - |
| Net margin | - | - | 20.07% | 19.27% | 14.46% | 25.2% | - | 19.39% | 19.01% | 12.14% | 8.5% | 9.73% | - | 14.11% | 7.98% | 15.59% | - | - |
| EPS 2 | - | - | 0.5900 | - | 0.2900 | 1.260 | - | 0.6900 | - | 0.3000 | 0.4300 | - | - | 0.5928 | 0.2352 | 1.090 | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.7788 | - | - | - | 0.8525 |
| Announcement Date | 3/22/22 | 4/27/22 | 8/28/22 | 8/28/22 | 10/25/22 | 3/29/23 | 4/26/23 | 8/28/23 | 8/28/23 | 10/29/23 | 4/25/24 | 4/25/24 | 4/25/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,986 | 2,452 | 1,941 | 2,585 | 3,124 | 3,485 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 882 | 416 | 339 | 1,182 | 1,360 | 1,474 |
| ROE (net income / shareholders' equity) | 29% | 20.5% | 13.2% | 17.1% | 18.7% | 17.2% |
| ROA (Net income/ Total Assets) | 23.3% | 16.8% | 10.6% | 14.2% | 15.8% | 15.3% |
| Assets 1 | 3,707 | 6,266 | 7,113 | 8,041 | 9,405 | 9,828 |
| Book Value Per Share 2 | 11.20 | 13.10 | 13.80 | 15.90 | 19.00 | 21.10 |
| Cash Flow per Share 2 | 2.830 | 1.820 | 1.440 | 2.950 | 3.470 | 3.990 |
| Capex 1 | 270 | 353 | 271 | 270 | 263 | 241 |
| Capex / Sales | 6.72% | 7.05% | 4.91% | 3.85% | 3.09% | 2.63% |
| Announcement Date | 3/22/22 | 3/29/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
53.4
CNY
Average target price
75.99
CNY
Spread / Average Target
+42.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.67% | 3.1B | |
| +0.32% | 262B | |
| +18.76% | 20.37B | |
| -.--% | 19.29B | |
| +16.91% | 12.64B | |
| -16.59% | 8.94B | |
| +33.93% | 8.62B | |
| +9.55% | 5.93B | |
| -12.08% | 3.92B | |
| -16.83% | 3.84B |
- Stock Market
- Equities
- 300957 Stock
- Financials Yunnan Botanee Bio-Technology Group Co.LTD
